JP2017508000A5 - - Google Patents

Download PDF

Info

Publication number
JP2017508000A5
JP2017508000A5 JP2016563908A JP2016563908A JP2017508000A5 JP 2017508000 A5 JP2017508000 A5 JP 2017508000A5 JP 2016563908 A JP2016563908 A JP 2016563908A JP 2016563908 A JP2016563908 A JP 2016563908A JP 2017508000 A5 JP2017508000 A5 JP 2017508000A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
eno1
subject
diabetes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016563908A
Other languages
English (en)
Japanese (ja)
Other versions
JP6644006B2 (ja
JP2017508000A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/011275 external-priority patent/WO2015106295A2/en
Publication of JP2017508000A publication Critical patent/JP2017508000A/ja
Publication of JP2017508000A5 publication Critical patent/JP2017508000A5/ja
Application granted granted Critical
Publication of JP6644006B2 publication Critical patent/JP6644006B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016563908A 2014-01-13 2015-01-13 エノラーゼ１（ｅｎｏ１）組成物及びその使用 Expired - Fee Related JP6644006B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201461926913P 2014-01-13 2014-01-13
US61/926,913 2014-01-13
US201462009783P 2014-06-09 2014-06-09
US62/009,783 2014-06-09
US201562100881P 2015-01-07 2015-01-07
US62/100,881 2015-01-07
PCT/US2015/011275 WO2015106295A2 (en) 2014-01-13 2015-01-13 Enolase 1 (eno1) compositions and uses thereof

Publications (3)

Publication Number Publication Date
JP2017508000A JP2017508000A (ja) 2017-03-23
JP2017508000A5 true JP2017508000A5 (enExample) 2018-02-22
JP6644006B2 JP6644006B2 (ja) 2020-02-12

Family

ID=53524434

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016563909A Expired - Fee Related JP6629234B2 (ja) 2014-01-13 2015-01-13 エノラーゼ１（ｅｎｏ１）組成物及びその使用
JP2016563908A Expired - Fee Related JP6644006B2 (ja) 2014-01-13 2015-01-13 エノラーゼ１（ｅｎｏ１）組成物及びその使用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2016563909A Expired - Fee Related JP6629234B2 (ja) 2014-01-13 2015-01-13 エノラーゼ１（ｅｎｏ１）組成物及びその使用

Country Status (14)

Country Link
US (4) US10188708B2 (enExample)
EP (2) EP3094341B1 (enExample)
JP (2) JP6629234B2 (enExample)
KR (1) KR20160106175A (enExample)
CN (3) CN106102835B (enExample)
AU (2) AU2015204452A1 (enExample)
BR (1) BR112016016153A2 (enExample)
CA (2) CA2936691A1 (enExample)
EA (1) EA201691420A1 (enExample)
HK (1) HK1231425A1 (enExample)
IL (1) IL246720A0 (enExample)
MX (1) MX2016009102A (enExample)
SG (1) SG11201605698XA (enExample)
WO (2) WO2015106296A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160106175A (ko) 2014-01-13 2016-09-09 버그 엘엘씨 에놀라아제 1 조성물들 및 이의 용도
WO2016210008A1 (en) * 2015-06-22 2016-12-29 Berg Llc Compositions comprising eno1 and their use in methods of treating obesity or overweight and reducing weight gain
WO2017062363A1 (en) * 2015-10-05 2017-04-13 Joslin Diabetes Center Methods of use of betatrophin
EP3465200A4 (en) 2016-06-05 2020-07-08 Berg LLC PATIENT STRATIFICATION SYSTEMS AND METHODS AND IDENTIFICATION OF POTENTIAL BIOMARKERS
CN107991493B (zh) * 2017-11-22 2020-03-31 中国医科大学附属第一医院 抗eno1自身抗体在对ait孕妇筛查和预测流产风险中的应用
CN112111462B (zh) * 2020-09-14 2022-08-23 兰州大学 烯醇化酶eno1单克隆抗体及其应用
CN118251242A (zh) * 2021-11-26 2024-06-25 上毅生物科技股份有限公司 通过靶向细胞外α-烯醇酶调节糖酵解以治疗人类疾病的方法
CN114533902A (zh) * 2022-02-28 2022-05-27 河南师范大学 一种过表达lrrc15基因的质粒载体及其制备方法和应用
CN115786317A (zh) * 2022-12-12 2023-03-14 江苏三联生物工程股份有限公司 重组神经元特异性烯醇化酶及其制备方法与应用

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE244576T1 (de) 1992-09-25 2003-07-15 Neorx Corp Therapeutischer inhibitor der vaskulären glatten muskelzellen
HUT77047A (hu) 1994-10-25 1998-03-02 Immulogic Pharmaceutical Corporation Szklerózis multiplex kezelésére szolgáló készítmények és kezelések
US5552524A (en) 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
US20030044795A1 (en) 1996-09-06 2003-03-06 Inger Byrajalsen Biochemical markers of the human endometrium
US7078375B1 (en) 1996-10-25 2006-07-18 Peter Mose Larsen Diabetes-mediating proteins and therapeutic uses thereof
US6329501B1 (en) 1997-05-29 2001-12-11 Auburn University Methods and compositions for targeting compounds to muscle
IL148225A0 (en) 1999-09-01 2002-09-12 Subsidiary No 3 Inc Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes
WO2001016323A2 (en) 1999-09-01 2001-03-08 Subsidiary N0.3, Inc. Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes
AU2470101A (en) 1999-10-25 2001-05-08 Affymetrix, Inc. Genetic sequences associated with neural cell proliferation and disease
CA2399058A1 (en) 2000-02-02 2001-08-09 Transgene S.A. Targeting peptides
US20030203372A1 (en) 2000-12-08 2003-10-30 Ward Neil Raymond Analysis method
US20040236091A1 (en) 2001-03-28 2004-11-25 Chicz Roman M. Translational profiling
US20040058326A1 (en) 2001-07-27 2004-03-25 Brooksbank Robert Alan Identification and use of molecules implicated in pain
US20050191627A1 (en) 2001-09-28 2005-09-01 Incyte Corporation Enzymes
WO2003064501A1 (en) 2002-01-31 2003-08-07 Clarke Slemon Conformationally restricted compounds as dendrimer cores
US20050222023A1 (en) 2002-02-07 2005-10-06 Hans-Peter Hauser Albumin-fused kunitz domain peptides
JP2004081111A (ja) 2002-08-27 2004-03-18 Yamaguchi Technology Licensing Organization Ltd 虚血性心疾患の治療薬として新規活性を有するα−エノラーゼおよびその利用法
EP2364716A3 (en) 2002-11-08 2012-01-11 Genentech, Inc. Compositions and methods for the treatment of natural killer cell related diseases
CN101518533A (zh) * 2002-12-06 2009-09-02 法布罗根股份有限公司 脂肪调节
US8124582B2 (en) 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
WO2004055519A2 (en) 2002-12-17 2004-07-01 Sinogenomax Co. Ltd. Specific markers for pancreatic cancer
WO2004061088A2 (en) 2002-12-30 2004-07-22 Ppd Development, Lp Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes
US20060263336A1 (en) 2003-03-24 2006-11-23 Caplan Arnold I Cell targeting methods and compositions
US7473531B1 (en) 2003-08-08 2009-01-06 Colora Corporation Pancreatic cancer targets and uses thereof
WO2005019258A2 (en) 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
JP2005073621A (ja) 2003-09-01 2005-03-24 Japan Science & Technology Agency 脳腫瘍マーカーと脳腫瘍の診断方法
EP1667710A2 (en) 2003-10-03 2006-06-14 VIB vzw Means and methods for the recruitment and identification of stem cells
US8133733B2 (en) * 2003-10-24 2012-03-13 Gencia Corporation Nonviral vectors for delivering polynucleotides to target tissues
WO2006004249A1 (en) 2004-07-06 2006-01-12 Kuhnil Pharmaceutical. Co., Ltd Composition for the diagnosis of retinal vascular disease comprising aldolase and method for diagnosis using it
WO2007046818A2 (en) 2004-11-16 2007-04-26 Board Of Regents, The University Of Texas System Compositions and methods related to synchronous selection of homing peptides for multiple tissues by in vivo phage display
EP1843781B1 (en) 2005-01-03 2015-03-18 Jeon, Sook-yeong Composition for prevention, treatment and diagnosis of chronic inflammatory airway diseases
US7608413B1 (en) 2005-03-25 2009-10-27 Celera Corporation Kidney disease targets and uses thereof
WO2006108052A2 (en) 2005-04-06 2006-10-12 Genzyme Corporation Peg and polysialic lysosomal enzyme conjugates via acid labile linkers for therapeutic targeting
US20070248628A1 (en) 2005-12-06 2007-10-25 Keller Lorraine H Immunogens in cancer stem cells
TWI304443B (en) 2005-12-30 2008-12-21 Nat Health Research Institutes Alpha-enolase specific antibody and method of use
EP2121747A2 (en) 2006-07-27 2009-11-25 Oxford Genome Sciences (UK) Limited New protein isoforms and uses thereof
NZ576409A (en) 2006-09-29 2012-02-24 Ribovax Biotechnologies Sa A phosphorylated isoform of human alpha-enolase used in pancreatic ductal adenocarcinoma treatment and diagnosis
US20100047256A1 (en) 2007-01-25 2010-02-25 Imperial Innovations Limited Methods
WO2008134761A2 (en) 2007-04-30 2008-11-06 Intezyne Technologies, Inc. Modification of biological targeting groups for the treatment of cancer
AU2008273096B2 (en) 2007-07-12 2013-05-02 Academisch Ziekenhuis Leiden Molecules for targeting compounds to various selected organs or tissues
EP2080812A1 (en) 2008-01-18 2009-07-22 Transmedi SA Compositions and methods of detecting post-stop peptides
JP5429707B2 (ja) 2008-03-27 2014-02-26 国立大学法人群馬大学 微粒子およびその製造方法
US20110130346A1 (en) * 2008-05-30 2011-06-02 Isis Innovation Limited Peptide conjugates for delvery of biologically active compounds
JP2011528557A (ja) 2008-07-18 2011-11-24 ヒルズ・ペット・ニュートリシャン・インコーポレーテッド 過体重動物と関連する障害を治療するための組成物および方法
EP2194382A1 (en) 2008-12-03 2010-06-09 Universität des Saarlandes An in-vitro method or assay for detecting a tumor or a cancerous disease by screening for antibodies
US20110269665A1 (en) 2009-06-26 2011-11-03 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
IT1398782B1 (it) 2009-09-11 2013-03-18 Novelli Peptide monofosforilato isolato derivato dall'alfa-enolasi umana utile per la diagnosi e il trattamento dell'adenocarcinoma pancreatico, anticorpi diretti contro il suddetto peptide monofosforilato e loro usi.
WO2011064552A1 (en) 2009-11-30 2011-06-03 Isis Innovation Limited Conjugates for delivery of biologically active compounds
WO2011072290A2 (en) 2009-12-11 2011-06-16 The Regents Of The University Of Michigan Targeted dendrimer-drug conjugates
CN103118698A (zh) 2010-05-28 2013-05-22 意识-Nrg公司 神经调节素同种型，神经调节素多肽和其使用
EP2638058B1 (en) 2010-11-12 2017-01-11 Merck Sharp & Dohme Corp. Enolase peptide conjugate vaccines against staphylococcus aureus
JP2014517832A (ja) 2011-05-10 2014-07-24 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 自己免疫疾患を治療するための方法及び医薬組成物
GB201113814D0 (en) 2011-08-10 2011-09-28 Proteome Sciences R & D Gmbh & Co Kg Materials and methods for determining sensitivity potential of compounds
WO2013030569A2 (en) 2011-08-30 2013-03-07 Michael John Gait Peptides
HUE045359T2 (hu) 2011-12-14 2019-12-30 Univ Texas Kollaterális gén inaktiváló biomarkerek és célsejtek a rákterápiában
WO2014018851A1 (en) 2012-07-26 2014-01-30 Joslin Diabetes Center, Inc. Predicting and treating diabetic complications
US10888625B2 (en) 2012-10-30 2021-01-12 Particle Sciences, Inc. Drug delivery particle formulations with targeting moieties
KR20160106175A (ko) 2014-01-13 2016-09-09 버그 엘엘씨 에놀라아제 1 조성물들 및 이의 용도
WO2016210008A1 (en) 2015-06-22 2016-12-29 Berg Llc Compositions comprising eno1 and their use in methods of treating obesity or overweight and reducing weight gain
WO2017011836A1 (en) 2015-07-16 2017-01-19 Berg Llc Enolase 1 (eno1) compositions and uses thereof

Similar Documents

Publication Publication Date Title
JP2017508000A5 (enExample)
EP3134552B1 (en) Methods, processes, devices and kits for the measurement of post traumatic stress disorder microrna markers
US10895572B2 (en) Autophagy-related nourin gene-based RNA network as early biomarkers for cardiac patients
US12247257B2 (en) Blood biomarkers of stroke
Guo et al. Combined use of circulating miR-133a and NT-proBNP improves heart failure diagnostic accuracy in elderly patients
Ping et al. Effects of variation in retinol binding protein 4 gene and adipose specific expression of gestational diabetes in Beijing, China
Biener et al. Diagnostic value of circulating microRNAs compared to high-sensitivity troponin T for the detection of non-ST-segment elevation myocardial infarction
KR102154816B1 (ko) Hla-b*1301 대립유전자의 용도
WO2018220185A1 (en) Novel circular rna biomarkers for heart failure
US20160145612A1 (en) Diagnosis and treatment of metabolic disorders
Hai et al. Relationship between inosine triphosphate genotype and outcome of extended therapy in hepatitis C virus patients with a late viral response to pegylated‐interferon and ribavirin
WO2018094021A1 (en) Steroid resistance in nephrotic syndrome
Pisani et al. Proteomic insights on the metabolism in inflammatory bowel disease
Rurali et al. Soluble EMMPRIN levels discriminate aortic ectasia in Marfan syndrome patients
US20170307609A1 (en) Methods for Treating Sepsis and Biomarkers Related Thereto
US20160244835A1 (en) Urinary neuropilin-1 (nrp-1) as a prognostic marker for nephritis and lupus nephritis
WO2022093757A1 (en) Kits, reagents and methods for the assessment of liver diseases
WO2019185864A1 (en) Biomarkers for diabetes therapy
JP2006014722A (ja) 遺伝子マーカー及びその利用
KR20200061902A (ko) 당뇨병성 신증 진단을 위한 마이크로rna 바이오마커 및 이의 용도
Hussien et al. Plasma MiRNA-208b as a biomarker for detection of cardiotoxicity induced by acute cardiovascular drugs poisoning
KR102165841B1 (ko) 당뇨병 진단을 위한 마이크로RNA let-7b 또는 마이크로RNA-664a 바이오마커 및 이의 용도
Campisi et al. Telomere integrity, epigenetic aging, and genetic burden shape biological aging trajectories in idiopathic pulmonary fibrosis
Fathy et al. Assessment of interleukin 28B genotype as a predictor of response to combined therapy with pegylated interferon plus ribavirin in HCV infected Egyptian patients
KR102658118B1 (ko) Fyb 유전자를 이용한 조기발병연령을 가진 우울증진단용 바이오마커 조성물, 이를 이용한 조기발병연령을 가진 우울증진단에 대한 정보제공방법 및 진단키트